Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2767109 | 1.00 | KCNH2 (0.83) | KCNH2TOP2A | |
| SCHEMBL5136329 | 1.00 | KCNH2 (0.83) | KCNH2TOP2A | |
| Hydrochloric Acid SCHEMBL2769151 | 0.99 | KCNH2 (0.82) | KCNH2TOP2A | |
| SCHEMBL2933693 | 0.94 | KCNH2 (0.73) | KCNH2TOP2A | |
| Hydrochloric Acid SCHEMBL2939439 | 0.93 | KCNH2 (0.72) | KCNH2TOP2A | |
| Hydrochloric Acid SCHEMBL3561145 | 0.93 | KCNH2 (0.72) | KCNH2TOP2A | |
| SCHEMBL14001973 | 0.91 | KCNH2 (0.70) | KCNH2TOP2A | |
| SCHEMBL2767874 | 0.91 | KCNH2 (0.70) | KCNH2TOP2A | |
| SCHEMBL2767770 | 0.91 | KCNH2 (0.70) | KCNH2TOP2A | |
| SCHEMBL13244728 | 0.91 | KCNH2 (0.71) | KCNH2TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | BALLELL-PAGES LLUIS | 2010-07-22 | — | — | US | claimed |
| US-7732460-B2 | Heterocyclic compounds, their preparation and their use as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | claimed |
| EP-1963324-B1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2010-04-21 | — | — | EP | claimed |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | claimed |
| EP-2005995-A1 | Heterocyclic compounds for the treatment of tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | EP | claimed |
| US-20070185153-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | claimed |
| US-20260027101-A1 | BACTERIAL TOPOISOMERASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2024020068-A1 | BACTERIAL TOPOISOMERASE INHIBITORS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20230097866-A1 | BACTERIAL TOPOISOMERASE INHIBITORS DERIVED FROM ISOMANNIDE | OHIO STATE INNOVATION FOUNDATION | 2023-03-30 | — | — | US | disclosed |
| EP-4093216-A1 | BACTERIAL TOPOISOMERASE INHIBITORS DERIVED FROM ISOMANNIDE | Ohio State Innovation Foundation (US) | 2022-11-30 | — | — | EP | disclosed |
| US-11352349-B2 | Type II topoisomerase inhibitors and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | BALLELL-PAGES LLUIS | 2010-07-22 | — | — | US | disclosed |
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | BALLELL-PAGES LLUIS | 2010-07-22 | — | — | US | disclosed |
| WO-2009000745-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009000745-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | WO | disclosed |
| EP-2005995-A1 | Heterocyclic compounds for the treatment of tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | EP | disclosed |
| US-20070185153-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185153-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185153-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| WO-2007071936-A1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230097866-A1 | BACTERIAL TOPOISOMERASE INHIBITORS DERIVED FROM ISOMANNIDE | TOP2A, TOP1, TOP2B | KCNH2 36/4885TOP2A 1/4885 |
| US-20260027101-A1 | BACTERIAL TOPOISOMERASE INHIBITORS | TOP1, TOP2A, TOP2B | KCNH2 2730/4885TOP2A 2/4885 |
| US-11352349-B2 | Type II topoisomerase inhibitors and methods of making and using thereof | TOP2A, TOP1, TOP2B | KCNH2 3891/4885TOP2A 1/4885 |
| US-20070185153-A1 | COMPOUNDS | NRDC, NISCH, MRPL21 | KCNH2 3013/4885TOP2A 39/4885 |
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | SDHA, SDHB, NNT | KCNH2 2498/4885TOP2A 737/4885 |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | MRPL21, NACA, NISCH | KCNH2 1599/4885TOP2A 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.